Skip to main content
SpringerLink
Log in

Obesity and liver disease

  • Treatment News
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Conclusions

Obesity increases the risk for liver disease, including liver cancer. The mechanisms for this association are not well understood. At the very least, obesity might function as a comorbidity factor, accentuating processes (such as microsomal enzyme induction or pro-inflammatory cytokine production) that mediate liver damage caused by alcohol, hepatotoxic drugs, or certain viral infections. However, a growing body of evidence suggests that obesity-related insulin resistance plays a fundamental role in the initiation and progression of liver damage and liver cancer by altering the viability of liver cells. Efforts to delineate the molecular mechanisms that mediate insulin’s actions on cellular apoptosis and proliferation are increasing, and should help us design more effective therapies to prevent and treat obesity-related liver diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Stevens J, Cai J, Pamuk ER, et al.: The effect of age on the association between body-mass index and mortality. N Engl J Med 1998, 338(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  2. Andres R, Muller DC, Sorkin JD: Long-term effects of change in body weight on all-cause mortality: a review. Ann Intern Med 1993, 119:737–743.

    PubMed  CAS  Google Scholar 

  3. Manson JE, Wilett WC, Stampfer MJ, et al.: Body weight and mortality among women. N Engl J Med 1995, 333:677–685.

    Article  PubMed  CAS  Google Scholar 

  4. Lindsted KD, Singh PN: Body mass and 26-year risk of mortality among women who never smoked: findings from the Adventist Mortality Study. Am J Epidemiol 1997, 146:1–11.

    PubMed  CAS  Google Scholar 

  5. Naveau S, Giraud V, Borotto E, et al.: Excess weight risk factor for alcoholic liver disease. Hepatology 1997, 25:108–111.

    Article  PubMed  CAS  Google Scholar 

  6. Poupon RY, Serfaty LD, Amorim M, et al.: Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C. Hepatology 1999, 30:406A.

    Google Scholar 

  7. Hodgson M, Van Thiel DH, Goodman-Klein B: Obesity and hepatotoxin risk factors for fatty liver disease. Br J Industr Med 1991, 48:690–695.

    CAS  Google Scholar 

  8. Ratziu V, Giral P, Charlotte F, et al.: Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117–1123.

    Article  PubMed  CAS  Google Scholar 

  9. Heston W, Vlhakis G: Genetic obesity and neoplasia. J Natl Cancer Inst 1962, 29:197–209.

    PubMed  CAS  Google Scholar 

  10. Galambos J: Natural history of alcoholic hepatitis III: histologic changes. Gastroenterology 1972, 56:515–522.

    Google Scholar 

  11. Morgan MY: The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol 1994, 2(suppl):335–343.

    CAS  Google Scholar 

  12. Pequignot G, Tuyns AS, Berta JL: Ascitic cirrhosis in relationship to alcohol consumption. Int J Epidemiol 1978, 7:113–120.

    Article  PubMed  CAS  Google Scholar 

  13. Lelbach WK: Epidemiology of alcoholic liver disease. Prog Liv Dis 1976, 5:494–513.

    CAS  Google Scholar 

  14. Iturriaga H, Bunout D, Hirsch S, Ugarte G: Overweight as a risk factor or a predictive sign of histological damage in alcoholics. Am J Clin Nutr 1988, 47:235–238.

    PubMed  CAS  Google Scholar 

  15. Bellentani S, Tiribelli C, Saccoccio G, et al.: Prevalence of chronic liver disease in the general population of northern Italy: the Dyonisos study. Hepatology 1994, 20:1442–1449.

    PubMed  CAS  Google Scholar 

  16. Braillon A, Capron JP, Herve MA, et al.: Liver in obesity. Gut 1985, 26:133–139.

    PubMed  CAS  Google Scholar 

  17. Ludwig J, Viggiano RT, McGill DB: Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:342–348.

    Google Scholar 

  18. Clain DJ, Lefkowitch JH: Fatty liver disease in morbid obesity. Gastroenerol Clin North Am 1987, 16:239–252.

    CAS  Google Scholar 

  19. Fiore G, Fera G, Napoli N, et al.: Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol. 1996, 8:125–129.

    Article  PubMed  CAS  Google Scholar 

  20. Bizzaro N, Tremolada F, Casarin C, et al.: Serum alanine aminotransferase levels among volunteer blood donors: effect of sex, alcohol intake and obesity. Ital J Gastroenterol 1992, 24:237–241.

    PubMed  CAS  Google Scholar 

  21. Anderson NA, Raafat A, Shwe KH, et al.: UK multicentre study on blood donors for surrogate markers of non-A, non-B hepatitis. Part I: Alanine transferase and anti-HBc testing. Transfus Med 1992, 2:301–310.

    PubMed  CAS  Google Scholar 

  22. Lozano M, Cid J, Bedini JL, et al.: Study of serum alanine-aminotransferase levels in blood donors in Spain. Haematologica 1998, 83:237–239.

    PubMed  CAS  Google Scholar 

  23. Goncales Junior FL, Stucchi RS, Papaiordanou PM, et al.: Elevated alanine aminotransferase (ALT) in blood donors: an assessment of the main associated conditions and its relationship to the development of hepatitis C. Rev Inst Med Trop Sao Paulo 1998, 40:219–224.

    PubMed  Google Scholar 

  24. Camps J, Crisostomo S, Garcia-Granero M, et al.: Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993, 34:1714–1717.

    PubMed  CAS  Google Scholar 

  25. Cotrim HP, Andrade ZA, Parana R, et al.: Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999, 19:299–304.

    Article  PubMed  CAS  Google Scholar 

  26. de la Maza MP, Hirsch S, Petermann M, et al.: Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000, 24:605–610.

    PubMed  Google Scholar 

  27. De Craemer D, Pauwels M, Van den Branden C: Alterations of peroxisomes in steatosis of the human liver: a quantitative study. Hepatology 1995, 22:744–752.

    Article  PubMed  Google Scholar 

  28. Teli M, James OF, Burt AD, et al.: A natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714–1717.

    PubMed  CAS  Google Scholar 

  29. el-Hassan AY, Ibrahim EM, al-Mulhim FA, et al.: Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992, 65:774–778.

    PubMed  CAS  Google Scholar 

  30. Nomura H, Kashiwagi S, Hayashi J, et al.: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988, 27:142–149.

    PubMed  CAS  Google Scholar 

  31. Caldwell SH, Oelsner DH, Iezzoni JC, et al.: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664–669.

    Article  PubMed  CAS  Google Scholar 

  32. Matteoni C, Younossi ZM, McCullough A: Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology 1999, 116:1413–1419.

    Article  PubMed  CAS  Google Scholar 

  33. Bacon B, Faravash MJ, Janney CG, et al.: Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology. 1994, 107:1103–1106.

    PubMed  CAS  Google Scholar 

  34. Powell EE, Searle J, Mortimer R: Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989, 97:1022–1024.

    PubMed  CAS  Google Scholar 

  35. Angulo P, Deach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 301356–62.

    Article  PubMed  CAS  Google Scholar 

  36. Drenick EJ, Roslyn JJ: Cure of arthritis-dermatitis syndrome due to intestinal bypass by resection of nonfunction segment of blind loop. Dig Dis Sci 1990, 35:656–660.

    Article  PubMed  CAS  Google Scholar 

  37. Jorizzo JL, Apisarnthanarax P, Subrt P, et al.: Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrome. Arch Intern Med 1983, 143:457–461.

    Article  PubMed  CAS  Google Scholar 

  38. Burke GW, Cirocco R, Hensely G, et al.: Liver transplantation for cirrhosis following jejunoileal bypass. Regional cytokine differences associated with pathological changes in the tranplanted liver. Transplantation 1992, 54:374–377.

    Article  PubMed  Google Scholar 

  39. Cope K, Risby T, Diehl AM: Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340–1347.

    Article  PubMed  CAS  Google Scholar 

  40. Rosenbaum M, Leibel RL, Hirsch J: Obesity. N Engl J Med 1997, 337:396–407.

    Article  PubMed  CAS  Google Scholar 

  41. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 1993, 119:655–660.

    PubMed  CAS  Google Scholar 

  42. Powell EE, Cooksley GE, Hanson R, et al.: The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients follow for up to 21 years. Hepatology 1990, 11:74–80.

    Article  PubMed  Google Scholar 

  43. Schoen RE, Tangen CM, Kuller LH, et al.: Increased blood glucose, insulin, body size and incident colorectal cancer. J Natl Cancer Inst 1999, 91:1147–1154.

    Article  PubMed  CAS  Google Scholar 

  44. La Vecchia C, Negri E, Franceschi S, et al.: A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994, 70:950–953.

    PubMed  Google Scholar 

  45. Wideroff L, Gridley G, Mellemkjaer L, et al.: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89:1360–1365.

    Article  PubMed  CAS  Google Scholar 

  46. Berkowitz D: Metabolic changes associated with obesity before and after weight reduction. JAMA 1964, 187:103–110.

    Google Scholar 

  47. Adler M, Schaffner F: Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979, 67:811–816.

    Article  PubMed  CAS  Google Scholar 

  48. Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986, 220:83–88.

    Article  PubMed  CAS  Google Scholar 

  49. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean noninsulindependent diabetic subjects. J Clin Endocrinol Metab 1991, 73:1294–1301.

    Article  PubMed  CAS  Google Scholar 

  50. Perriello G, Misericordia P, Volpi E, et al.: Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994, 43:920–928.

    Article  PubMed  CAS  Google Scholar 

  51. Melin B, Cherqui G, Blivet MJ, et al.: Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 1990, 39:1089–1095.

    Article  PubMed  CAS  Google Scholar 

  52. Lin HZ, Yang SQ, Kujhada F, et al.: Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice. Nat Med 2000, 6:998–1003.

    Article  PubMed  CAS  Google Scholar 

  53. El-Mir MY, Nogueira V, Fontaine E, et al.: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000, 275:223–228.

    Article  PubMed  CAS  Google Scholar 

  54. Kohlroser J, Mathai J, Reichheld J, et al.: Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and drug Administration. Am J Gastroenterol 2000, 95:272–276.

    Article  PubMed  CAS  Google Scholar 

  55. Kakuma T, Lee Y, Higa M, et al.: Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci USA 2000, 97:8536–8541.

    Article  PubMed  CAS  Google Scholar 

  56. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999, 96:7473–7478.

    Article  PubMed  CAS  Google Scholar 

  57. Capron JP, Herve MA, Ginestron JL, et al.: Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983, 1:446–449.

    Article  PubMed  CAS  Google Scholar 

  58. Campfield LA, Smith FJ, Burn P: The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Horm Metab Res 1996, 28:619–632.

    Article  PubMed  CAS  Google Scholar 

  59. Pelleymounter MA, Cullen MF, Baker MB, et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540–543.

    Article  PubMed  CAS  Google Scholar 

  60. Shimomura I, Hammer RE, Ikemoto S, et al.: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999, 401:73–76.

    Article  PubMed  CAS  Google Scholar 

  61. DiLuzio N, Costales F: Inhibition of ethanol and carbon tetrachloride induced fatty liver by antioxidants. Exp Mol Pathol 1965, 4:141–145.

    Article  CAS  Google Scholar 

  62. Lavine JE: Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734–738.

    Article  PubMed  CAS  Google Scholar 

  63. Capron JP, Delamarre M, Dupas JL, et al.: Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982, 54:374–377.

    Google Scholar 

  64. Vyberg M, Ravn V, Andersen B: Patterns of progression of liver injury following jejunoileal bypass for morbid obesity. Liver 1987, 7:271–276.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, The Johns Hopkins University, 912 Ross Research Building, 720 Rutland Street, 21205, Baltimore, MD, USA

    Ayman Koteish MD (Fellow at the Division of Gastroenterology and Hepatology at Johns Hopkins University) & Anna Mae Diehl MD (Professor of Medicine at the Division of Gastroenterology at Johns Hopkins Unviersity)

Authors
  1. Ayman Koteish MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Mae Diehl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koteish, A., Diehl, A.M. Obesity and liver disease. Curr Treat Options Gastro 4, 101–105 (2001). https://doi.org/10.1007/s11938-001-0020-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-001-0020-8

Search

Navigation